文献速递脑血管病

急性卒中合并癌症患者血管内取栓术后的结局探究

Investigating Outcomes Post-Endovascular Thrombectomy in Acute Stroke Patients With Cancer.
PubMed 文献 · Neurology · 2022-12-05

该研究基于美国全国住院患者样本(NIS)2016至2019年数据,纳入2,677,200例急性缺血性卒中住院患者,其中228,800例(8.5%)合并癌症;132,210例接受血管内取栓术(EVT),其中8,935例(6.8%)合并癌症。经倾向评分匹配分析,合并癌症的EVT患者颅内出血发生率(OR 1.03,CI 0.79-1.33,p=0.90)及出院回家几率与无癌症患者相似,但住院超过10天的比例显著更高(OR 1.34,CI 1.07-1.68,p=0.01);合并转移性癌症者住院死亡率更高(OR 2.72,CI 1.52-4.90,p<0.01)。作者认为,符合再灌注治疗标准的急性缺血性卒中患者,在合并癌症诊断的情况下可考虑接受EVT。

要点

  • 合并癌症的急性缺血性卒中患者接受EVT后颅内出血风险与无癌症者相似(OR 1.03)。
  • 合并癌症者EVT后住院超过10天的 odds 显著更高(OR 1.34,p=0.01)。
  • 合并转移性癌症者EVT后住院死亡率更高(OR 2.72,p<0.01)。

核心结论

  • 在当代医疗实践中,合并癌症或转移性癌症的急性卒中患者接受EVT后,颅内出血发生率和良好出院结局与无癌症患者相似。
  • 作者认为,符合再灌注治疗标准的急性缺血性卒中患者,在合并癌症诊断的情况下可考虑接受EVT。

研究设计与样本

  • 基于美国全国住院患者样本(NIS)的回顾性数据库研究,查询2016至2019年急性缺血性卒中住院记录并识别癌症患者。
  • 研究期间共2,677,200例急性缺血性卒中住院患者,其中228,800例(8.5%)合并癌症;132,210例接受EVT,其中8,935例(6.8%)合并癌症。
  • 采用倾向评分匹配分析接受EVT患者的颅内出血风险、住院时长和出院去向等主要结局。

主要发现

  • 合并癌症的EVT患者中超过20%获得常规出院回家(无需服务)的良好结局。
  • 经调整倾向评分分析,合并癌症的EVT患者颅内出血发生率与无癌症患者相似(OR 1.03,CI 0.79-1.33,p=0.90),出院回家几率相似,但住院超过10天的比例显著更高(OR 1.34,CI 1.07-1.68,p=0.01)。
  • 合并转移性癌症的EVT患者颅内出血发生率与无癌症患者相似(OR 1.03,CI 0.64-1.67,p=1.00),常规出院可能性相似(OR 0.83,CI 0.51-1.35,p=0.54),但住院死亡率更高(OR 2.72,CI 1.52-4.90,p<0.01)。

临床怎么用

  • 作者认为,符合再灌注治疗标准的急性缺血性卒中患者,在合并癌症诊断的情况下可考虑接受EVT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cancer is a common comorbidity in patients with acute ischemic stroke (AIS). Randomized controlled trials that established endovascular thrombectomy (EVT) as the standard of care for large vessel occlusion generally excluded patients with cancer. As such, the clinical benefits of endovascular thrombectomy in the cancer population are currently poorly established. We examine clinical outcomes of patients with cancer who underwent EVT using a large inpatient database, the National Inpatient Sample (NIS). METHODS: The NIS was queried for AIS admission between 2016 and 2019, and patients with cancer were identified. Baseline demographics, comorbidities, reperfusion therapies, and outcomes were compared between patients with AIS with and without cancer. For patients who underwent EVT, propensity score matching was used to study primary outcomes such as risk of intracranial hemorrhage, hospital length of stay, and discharge disposition. RESULTS: During the study period, 2,677,200 patients were hospitalized with AIS, 228,800 (8.5%) of whom had a diagnosis of cancer. A total of 132,210 patients underwent EVT, of which 8,935 (6.8%) had cancer. Over 20% of patients with cancer who underwent EVT had a favorable outcome of a routine discharge home without services. On adjusted propensity score analysis, patients with cancer who underwent EVT had similar rates of intracranial hemorrhage (OR 1.03, CI 0.79-1.33, p = 0.90) and odds of a discharge home, with a significantly higher rate of prolonged hospitalization greater than 10 days (OR 1.34, CI 1.07-1.68, p = 0.01). Compared with patients without cancer, patients with metastatic cancer who underwent EVT also had similar rates of intracranial hemorrhage (OR 1.03, CI 0.64-1.67, p = 1.00) and likelihood of routine discharge (OR 0.83, CI 0.51-1.35, p = 0.54) but higher rates of in-hospital mortality (OR 2.72, CI 1.52-4.90, p < 0.01). DISCUSSION: Our findings show that in contemporary medical practice, patients with acute stroke with comorbid cancer or metastatic cancer who undergo endovascular thrombectomy have similar rates of intracranial hemorrhage and favorable discharges as patients without cancer. This suggests that patients with AIS who meet the criteria for reperfusion therapy may be considered in the setting of a comorbid cancer diagnosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shapiro SD, Vazquez S, Das A, et al. Investigating Outcomes Post-Endovascular Thrombectomy in Acute Stroke Patients With Cancer. Neurology. 2022. PMID: 36123128. doi:10.1212/WNL.0000000000201208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。